Volpara’s software enables early detection of breast cancer by utilising its proprietary artificial intelligence (AI) technology to improve breast screening. The technology allows for the objective measurement of breast density, which is associated with breast cancer risk.
Sales are climbing in the huge US market, aided by the acquisition of US based specialist radiology clinic management software provider, MRS Systems in June 2019 for US$14.6m. This has increased the company’s access to number of US breast imaging clinics by five times.
Want to see other interesting ASX Healthcare Shares stocks?
Would you like to invest in VHT?
Get access to all our research on VHT + our current best stocks to buy now. 14 days free. No credit card required just enter your email and you're away.
START YOUR 14 DAY FREE TRIAL
No restrictions, no limits.
Get access to all of Under the Radar Report data FREE for 14 days.
NO CREDIT CARD REQUIRED
JOIN UNDER THE RADAR REPORT
Simply provide your details below to get started.